Masahiro Sakata

Fukuyama, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

Atezolizumab-Bevacizumab with or without Cisplatin-based HAIC for Unresectable HCC: A Randomized Phase 2 Trial.

Atezolizumab-Bevacizumab with or without Cisplatin-based HAIC for Unresectable HCC: A Randomized Phase 2 Trial.

Journal: JHEP reports : innovation in hepatology

Published: March 27, 2026

Borderline Resectable Classification Identifies Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab.

Borderline Resectable Classification Identifies Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: November 07, 2025

Association of Metabolic-Associated Steatotic Liver Disease With Clinical Outcomes of Durvalumab and Tremelimumab in Advanced Hepatocellular Carcinoma Patients: A Multicenter Study.

Association of Metabolic-Associated Steatotic Liver Disease With Clinical Outcomes of Durvalumab and Tremelimumab in Advanced Hepatocellular Carcinoma Patients: A Multicenter Study.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: May 27, 2025

Antitumor effects and immune-mediated adverse events of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma.

Antitumor effects and immune-mediated adverse events of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: October 04, 2024

Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy.

Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy.

Journal: PloS one

Published: July 16, 2024

Response to the letter: "Predictive factors for transition to conversion therapy in HCC using atezolizumab plus bevacizumab".

Response to the letter: "Predictive factors for transition to conversion therapy in HCC using atezolizumab plus bevacizumab".

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: April 21, 2024

Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real‑world practice.

Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real‑world practice.

Journal: Oncology letters

Published: March 01, 2024

True, True and Unrelated? A Case of 2 Nearby Gastric Lesions.

True, True and Unrelated? A Case of 2 Nearby Gastric Lesions.

Journal: The American journal of gastroenterology

Published: October 19, 2023

Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab.

Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: August 17, 2023

Pathogenesis of Severe Liver Injury in Patients with Anorexia Nervosa: A Report of Two Cases and a Literature Review.

Pathogenesis of Severe Liver Injury in Patients with Anorexia Nervosa: A Report of Two Cases and a Literature Review.

Journal: The Kurume medical journal

Published: September 21, 2022

Synchronous Double Primary Combined Hepatocellular-cholangiocarcinoma and Cholangiolocarcinoma in a Cirrhotic Liver.

Synchronous Double Primary Combined Hepatocellular-cholangiocarcinoma and Cholangiolocarcinoma in a Cirrhotic Liver.

Journal: Journal of clinical and translational hepatology

Published: August 07, 2022

Abnormal fucosylation of alpha-fetoprotein in patients with nonalcoholic steatohepatitis.

Abnormal fucosylation of alpha-fetoprotein in patients with nonalcoholic steatohepatitis.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: December 31, 2020

Showing 1-12 of 37

Last Updated: 09/26/2026